SuperGen's CLIMB technology identifies lead Pim kinase inhibitors

Dec 10 2007

SuperGen Inc. has announced the presentation of data that describe how its proprietary CLIMB technology was used in lead development and design of small molecule Pim kinase inhibitors (Poster 845, Abstract 2655).

This data is part of a series of presentations at the American Society of Hematology's 49th Annual Meeting taking place at the Georgia World Congress Center in Atlanta.

Entitled "Targeting Pim Kinases in Hematological Malignancies," the poster described how scientists used SuperGen's CLIMB(TM) technology to build a model to identify small molecule inhibitors of the Pim kinases, which are over- expressed in many cancer types, including acute myelogenous leukemia and acute lymphoblastic leukemia. Leads were screened to identify those with inhibitory activity with low nanomolar IC50 concentrations. Data support further development of the lead compounds in hematological malignancies.

"Using our CLIMB(TM) drug discovery process to model the three Pim kinases, we were able to identify several small molecule leads that appear to be highly effective inhibitors of the Pim kinase family," said Dr. David Bearss, SuperGen's Vice President, Chief Scientist. "We have also used this approach with other programs in our pipeline. Our CLIMB TM technology allows us to optimize lead drug candidates, decrease our drug discovery cycle time, and operate more efficiently."